Ncardia
Gustavo Mahler serves as the Chief Executive Officer at Cellistic and Ncardia since January 2023. Previously, Gustavo held the position of Venture Partner at Dynamk Capital LLC from May 2019 to December 2022 and was an Executive Board Member at Life Science Washington during the same period. Additionally, Gustavo had a significant tenure at AGC Biologics, where roles included Member of the Board of Directors, CEO, and President and Global Chief Operations Officer, overseeing all global operations. Responsibilities also included the management of manufacturing operations for CMC Icos Biologics as President. Board Member contributions were made at AbSci between June 2018 and June 2021. Gustavo's early career at Bayer Healthcare included serving as VP of Technical Operations, managing substantial manufacturing operations for Factor VIII. Educational credentials encompass a PhD and MBA from the University of Buenos Aires, alongside a Leadership and Management certification from MIT Sloan School of Management.
This person is not in any offices
Ncardia
Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications. Explore our website to learn more www.ncardia.com.